These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 18977148)

  • 41. A small HDM2 antagonist peptide and a USP7 inhibitor synergistically inhibit the p53-HDM2-USP7 circuit.
    Mukherjee S; Saha G; Roy NS; Naiya G; Ghosh MK; Roy S
    Chem Biol Drug Des; 2023 Jul; 102(1):126-136. PubMed ID: 37105726
    [TBL] [Abstract][Full Text] [Related]  

  • 42. hnRNP K: an HDM2 target and transcriptional coactivator of p53 in response to DNA damage.
    Moumen A; Masterson P; O'Connor MJ; Jackson SP
    Cell; 2005 Dec; 123(6):1065-78. PubMed ID: 16360036
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hexylitaconic acid: a new inhibitor of p53-HDM2 interaction isolated from a marine-derived fungus, Arthrinium sp.
    Tsukamoto S; Yoshida T; Hosono H; Ohta T; Yokosawa H
    Bioorg Med Chem Lett; 2006 Jan; 16(1):69-71. PubMed ID: 16246554
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inhibition of topoisomerase II catalytic activity by pyridoacridine alkaloids from a Cystodytes sp. ascidian: a mechanism for the apparent intercalator-induced inhibition of topoisomerase II.
    McDonald LA; Eldredge GS; Barrows LR; Ireland CM
    J Med Chem; 1994 Oct; 37(22):3819-27. PubMed ID: 7525959
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Modulation of the p53/MDM2 interplay by HAUSP inhibitors.
    Tavana O; Gu W
    J Mol Cell Biol; 2017 Feb; 9(1):45-52. PubMed ID: 27927749
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A second p53 binding site in the central domain of Mdm2 is essential for p53 ubiquitination.
    Ma J; Martin JD; Zhang H; Auger KR; Ho TF; Kirkpatrick RB; Grooms MH; Johanson KO; Tummino PJ; Copeland RA; Lai Z
    Biochemistry; 2006 Aug; 45(30):9238-45. PubMed ID: 16866370
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53.
    Honda R; Yasuda H
    EMBO J; 1999 Jan; 18(1):22-7. PubMed ID: 9878046
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Molecular modeling approaches in the discovery of new drugs for anti-cancer therapy: the investigation of p53-MDM2 interaction and its inhibition by small molecules.
    Lauria A; Tutone M; Ippolito M; Pantano L; Almerico AM
    Curr Med Chem; 2010; 17(28):3142-54. PubMed ID: 20666726
    [TBL] [Abstract][Full Text] [Related]  

  • 49.
    Al-Ghabkari A; Narendran A
    Cancer Biother Radiopharm; 2019 May; 34(4):252-257. PubMed ID: 30724592
    [No Abstract]   [Full Text] [Related]  

  • 50. A high-throughput screen measuring ubiquitination of p53 by human mdm2.
    Murray MF; Jurewicz AJ; Martin JD; Ho TF; Zhang H; Johanson KO; Kirkpatrick RB; Ma J; Lor LA; Thrall SH; Schwartz B
    J Biomol Screen; 2007 Dec; 12(8):1050-8. PubMed ID: 17989425
    [TBL] [Abstract][Full Text] [Related]  

  • 51. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.
    Lau LM; Nugent JK; Zhao X; Irwin MS
    Oncogene; 2008 Feb; 27(7):997-1003. PubMed ID: 17700533
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The oncoprotein SS18-SSX1 promotes p53 ubiquitination and degradation by enhancing HDM2 stability.
    D'Arcy P; Maruwge W; Ryan BA; Brodin B
    Mol Cancer Res; 2008 Jan; 6(1):127-38. PubMed ID: 18234968
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Loss of HAUSP-mediated deubiquitination contributes to DNA damage-induced destabilization of Hdmx and Hdm2.
    Meulmeester E; Maurice MM; Boutell C; Teunisse AF; Ovaa H; Abraham TE; Dirks RW; Jochemsen AG
    Mol Cell; 2005 May; 18(5):565-76. PubMed ID: 15916963
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Alternative strategies for targeting mouse double minute 2 activity with small molecules: novel patents on the horizon?
    Macchiarulo A; Giacchè N; Mancini F; Puxeddu E; Moretti F; Pellicciari R
    Expert Opin Ther Pat; 2011 Mar; 21(3):287-94. PubMed ID: 21342053
    [TBL] [Abstract][Full Text] [Related]  

  • 55. New Perspectives in the Chemistry of Marine Pyridoacridine Alkaloids.
    Plodek A; Bracher F
    Mar Drugs; 2016 Jan; 14(2):. PubMed ID: 26821033
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intrinsic ubiquitination activity of PCAF controls the stability of the oncoprotein Hdm2.
    Linares LK; Kiernan R; Triboulet R; Chable-Bessia C; Latreille D; Cuvier O; Lacroix M; Le Cam L; Coux O; Benkirane M
    Nat Cell Biol; 2007 Mar; 9(3):331-8. PubMed ID: 17293853
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Marine Pyridoacridine Alkaloids: Biosynthesis and Biological Activities.
    Ibrahim SR; Mohamed GA
    Chem Biodivers; 2016 Jan; 13(1):37-47. PubMed ID: 26765351
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of pyridoacridine alkaloids in a zebrafish phenotypic assay.
    Wei X; Bugni TS; Harper MK; Sandoval IT; Manos EJ; Swift J; Van Wagoner RM; Jones DA; Ireland CM
    Mar Drugs; 2010 Jun; 8(6):1769-78. PubMed ID: 20631869
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Targeting Hdm2 and Hdm4 in Anticancer Drug Discovery: Implications for Checkpoint Inhibitor Immunotherapy.
    Ntwasa M
    Cells; 2024 Jun; 13(13):. PubMed ID: 38994976
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Robust generation of lead compounds for protein-protein interactions by computational and MCR chemistry: p53/Hdm2 antagonists.
    Czarna A; Beck B; Srivastava S; Popowicz GM; Wolf S; Huang Y; Bista M; Holak TA; Dömling A
    Angew Chem Int Ed Engl; 2010 Jul; 49(31):5352-6. PubMed ID: 20575124
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.